The loss of the anti-tumor activity of NAMPT inhibitors in presence of bacteria supports the recent study by Shats et al. [24] reporting that bacteria can boost the mammalian host NAD+ and thereby confer resistance to NAMPT inhibitors in an in vivo setting of colon cancer. This evidence concerns the gene NAMPT and malignant colon neoplasm.